Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300912 | 1.00 | HSD11B1 (0.34) | HSD11B1CNR2PARP1NOS3NOS1 | |
| SCHEMBL23336233 | 0.79 | FPR2 (0.39) | PARP1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL23297036 | 0.77 | FPR2 (0.39) | PARP1NOS3NOS1 | |
| SCHEMBL797629 | 0.76 | L3MBTL3 (0.33) | HSD11B1PLA2G7 | |
| SCHEMBL5371521 | 0.72 | PARP1 (0.42) | PARP1ALDH1A1HRH3 | |
| SCHEMBL4517094 | 0.72 | JAK2 (0.40) | HSD11B1NOS3NOS1JAK2ALDH1A1 | |
| SCHEMBL5371518 | 0.71 | PARP1 (0.46) | PARP1ALDH1A1PKMHRH3 | |
| SCHEMBL22481540 | 0.70 | HSD11B1 (0.33) | HSD11B1PARP1JAK2 | |
| SCHEMBL13068884 | 0.69 | — | — | |
| SCHEMBL797228 | 0.68 | FPR2 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143429-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CRAWFORTH JAMES MICHAEL | 2009-06-04 | — | — | US | disclosed |
| EP-1912967-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012900-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143429-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR2, TACR1, TACR3 | HSD11B1 2823/4885CNR2 62/4885PARP1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.